Amyris Story

<div class='circular--portrait' style='background:#1A69FC;color: #ffffff;font-size:3em;'>AMR</div>
AMRS -- USA Stock  

USD 15.69  0.37  2.30%

Let's try to sum up what's happening with Amyris amid unprecedented political, and economic uncertainty. Amyris Inc is presently traded for 19.95. The entity has historical hype elasticity of 2.75. The average price elasticity to hype of competition is about 0.34. The firm is forecasted to increase in value after the next press release, with the price going to jump to 18.45. The latest volatility of headline impact on the company stock price is is way over 100 percent making price predictions on social media along less reliable. The price gain on the next news is estimated to be 17.82%, whereas the daily expected return is presently at 3.23%. Given the investment horizon of 30 days the next forecasted announcement will be in about 8 days.
Published over a month ago
View all stories for Amyris | View All Stories
Is Amyris (NASDAQ:AMRS) gaining more confidence from retail investors?
The company's average rating is Strong Buy from 4 analysts.
Our trade advice tool can cross-verify current analyst consensus on Amyris Inc and to analyze the company potential to grow in the current economic cycle.
The successful prediction of Amyris stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Amyris Inc, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Amyris based on Amyris hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Amyris's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Amyris's related companies.

Use Technical Analysis to project Amyris expected Price

Amyris technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Amyris technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Amyris trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Amyris utilizes its cash?

To perform a cash flow analysis of Amyris, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Amyris is receiving and how much cash it distributes out in a given period. The Amyris cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Amyris Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Amyris reported last year Net Cash Flow from Operations of (175.75 Million)

A Deeper Perspective

Amyris Inc reported the previous year's revenue of 133.93 M. Net Loss for the year was (350.93 M) with profit before overhead, payroll, taxes, and interest of 11.91 M.
 2018 2019 2020 2021 (projected)
Current Assets92.22 M73.61 M66.25 M74.15 M
Total Assets127.92 M160.97 M144.87 M160.5 M

Deferred Revenue Breakdown

Amyris Deferred Revenue yearly trend continues to be relatively stable with very little volatility. Deferred Revenue is likely to grow to about 1.2 M this year. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Amyris Deferred Revenue is relatively stable at the moment as compared to the past year. Amyris reported last year Deferred Revenue of 1.22 Million
2014
2015
2016
2017
2018
2019
2020
2021
201411.84 Million
201510.98 Million
20165.29 Million
20174.31 Million
20188.24 Million
20191.35 Million
20201.22 Million
20211.25 Million

Will Amyris growth be justifiable after the spike?

Standard deviation is down to 8.06. It may connote a possible volatility fall. Amyris Inc is displaying above-average volatility over the selected time horizon. Investors should scrutinize Amyris Inc independently to ensure intended market timing strategies are aligned with expectations about Amyris volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Amyris' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Amyris' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

The Current Takeaway on Amyris Investment

While many other companies under the specialty chemicals industry are still a bit expensive, Amyris may offer a potential longer-term growth to retail investors. To conclude, as of the 2nd of March 2021, we believe that Amyris is currently overvalued with average probability of distress in the next two years. Our actual 30 days buy-hold-sell advice on the enterprise is Strong Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Amyris Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com